NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation, it was noted that prostate cancer is more common in men aged over 60 and that African Caribbean men are three times more likely to develop prostate cancer than white men of the same age in the UK.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Differences in prevalence alone cannot be addressed within a technology appraisal. These potential equality issues are unlikely to be affected by Committee’s recommendations and would not lead to differences in access to treatment. The Committee will assess whether their recommendation restricts access to the technology for any group of people. During consultation on the scope, no evidence was received of differential access to therapy or prognosis in this group.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No changes to the draft scope were required. The background section of the draft scope already acknowledged that the incidence of prostate cancer increases with age and is higher in men of African-Caribbean family origin.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Helen Knight

Date: 02/04/2014